These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 24599933)

  • 1. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
    Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
    Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.
    Min Y; Adachi Y; Yamamoto H; Ito H; Itoh F; Lee CT; Nadaf S; Carbone DP; Imai K
    Cancer Res; 2003 Oct; 63(19):6432-41. PubMed ID: 14559833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.
    Friedbichler K; Hofmann MH; Kroez M; Ostermann E; Lamche HR; Koessl C; Borges E; Pollak MN; Adolf G; Adam PJ
    Mol Cancer Ther; 2014 Feb; 13(2):399-409. PubMed ID: 24296829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
    Gao J; Chesebrough JW; Cartlidge SA; Ricketts SA; Incognito L; Veldman-Jones M; Blakey DC; Tabrizi M; Jallal B; Trail PA; Coats S; Bosslet K; Chang YS
    Cancer Res; 2011 Feb; 71(3):1029-40. PubMed ID: 21245093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway.
    Doepfner KT; Spertini O; Arcaro A
    Leukemia; 2007 Sep; 21(9):1921-30. PubMed ID: 17581609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
    Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
    Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance.
    Li B; Xu WW; Guan XY; Qin YR; Law S; Lee NP; Chan KT; Tam PY; Li YY; Chan KW; Yuen HF; Tsao SW; He QY; Cheung AL
    Clin Cancer Res; 2016 Mar; 22(5):1243-55. PubMed ID: 26475334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor 1 mediates 5-fluorouracil chemoresistance in esophageal carcinoma cells through increasing survivin stability.
    Juan HC; Tsai HT; Chang PH; Huang CY; Hu CP; Wong FH
    Apoptosis; 2011 Feb; 16(2):174-83. PubMed ID: 21082354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway.
    Li B; Tsao SW; Li YY; Wang X; Ling MT; Wong YC; He QY; Cheung AL
    Int J Cancer; 2009 Dec; 125(11):2576-85. PubMed ID: 19551863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
    Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis.
    Nussbaum T; Samarin J; Ehemann V; Bissinger M; Ryschich E; Khamidjanov A; Yu X; Gretz N; Schirmacher P; Breuhahn K
    Hepatology; 2008 Jul; 48(1):146-56. PubMed ID: 18537183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell.
    Kalra N; Zhang J; Yu Y; Ho M; Merino M; Cao L; Hassan R
    Int J Cancer; 2012 Nov; 131(9):2143-52. PubMed ID: 22323052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.
    Ii M; Li H; Adachi Y; Yamamoto H; Ohashi H; Taniguchi H; Arimura Y; Carbone DP; Imai K; Shinomura Y
    Clin Cancer Res; 2011 Aug; 17(15):5048-59. PubMed ID: 21642381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
    Adachi Y; Li R; Yamamoto H; Min Y; Piao W; Wang Y; Imsumran A; Li H; Arimura Y; Lee CT; Imai K; Carbone DP; Shinomura Y
    Carcinogenesis; 2009 Aug; 30(8):1305-13. PubMed ID: 19493905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.